Sanofi launches Apidra SoloSTAR in USA
French drug major Sanofi-Aventis has launched Apidra (insulin gluisine) SoloSTAR, a pre-filled, disposable pen containing a rapid-acting insulin analog, in the USA.
The product is indicated for the treatment of adults with type 1 or type 2 diabetes, and children with the former. The launch follows the product's Food and Drug Administration approval in February (Marketletter March 9).
Apidra can be taken up to 20 minutes after starting a meal and be just as effective as other diabetes treatments that must be used at least 15 minutes before eating, according to the firm. The product comes in Sanofi's SoloSTAR prefilled, low-force injection pen, which has a dial-back safety feature to correct dose selection errors.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Today's issue
Company Spotlight
Copyright © The Pharma Letter 2025 | Headless Content Management with Blaze